1355990-07-6 Usage
Description
2-((1R,2R,3aS,9aS)-2-hydroxy-1-(S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalene-5-yloxylacetic acid ethyl ester is a complex organic compound with a unique molecular structure. It is characterized by its hexahydro-1H-cyclopenta[b]naphthalene core, which is substituted with various functional groups, including hydroxy and ethoxylacetic acid ester moieties. 2-((1R,2R,3aS,9aS)-2-hydroxy-1-(S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalene-5-yloxylacetic acid ethyl ester exhibits a high degree of stereoselectivity, with specific configurations at multiple chiral centers.
Uses
Used in Pharmaceutical Industry:
2-((1R,2R,3aS,9aS)-2-hydroxy-1-(S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalene-5-yloxylacetic acid ethyl ester is used as a pharmaceutical agent for the treatment of pulmonary arterial hypertension (PAH). Its application is based on its structural similarity to Treprostinil, a synthetic analog of Prostacyclin, which is known for its vasodilatory and antihypertensive properties. 2-((1R,2R,3aS,9aS)-2-hydroxy-1-(S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalene-5-yloxylacetic acid ethyl ester may offer an alternative or improved treatment option for PAH patients, potentially leading to better management of the disease and improved quality of life.
Used in Drug Delivery Systems:
In the field of drug delivery, 2-((1R,2R,3aS,9aS)-2-hydroxy-1-(S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalene-5-yloxylacetic acid ethyl ester can be utilized as a component in the development of novel drug delivery systems. Its unique molecular structure and functional groups may allow for targeted drug delivery, improved bioavailability, and enhanced therapeutic outcomes. This application could be particularly relevant in the treatment of various diseases, including cancer, where precise drug targeting and controlled release are crucial for effective treatment.
Used in Chemical Research:
2-((1R,2R,3aS,9aS)-2-hydroxy-1-(S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalene-5-yloxylacetic acid ethyl ester may also find use in chemical research, particularly in the study of stereochemistry, molecular recognition, and the development of new synthetic methods. Its complex structure and multiple chiral centers make it an interesting subject for researchers to explore and potentially use as a building block for the synthesis of other biologically active compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1355990-07-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,5,9,9 and 0 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1355990-07:
(9*1)+(8*3)+(7*5)+(6*5)+(5*9)+(4*9)+(3*0)+(2*0)+(1*7)=186
186 % 10 = 6
So 1355990-07-6 is a valid CAS Registry Number.
1355990-07-6Relevant articles and documents
Inhaled Treprostinil-Prodrug Lipid Nanoparticle Formulations Provide Long-Acting Pulmonary Vasodilation
Leifer, Franziska G.,Konicek, Donna M.,Chen, Kuan-Ju,Plaunt, Adam J.,Salvail, Dany,Laurent, Charles E.,Corboz, Michel R.,Li, Zhili,Chapman, Richard W.,Perkins, Walter R.,Malinin, Vladimir
, p. 605 - 614 (2018)
Treprostinil (TRE), a prostanoid analogue approved in the USA for the treatment of pulmonary arterial hypertension, requires continuous infusion or multiple dosing sessions per day for inhaled and oral routes of administration due to its short half-life. The inhaled drug is known to induce adverse systemic and local effects including headache, nausea, cough, and throat irritation which may be due at least in part to transiently high drug concentrations in the lungs and plasma immediately following administration [1]. To ameliorate these side effects and reduce dosing frequency we designed an inhaled slow-release TRE formulation. TRE was chemically modified to be an alkyl prodrug (TPD) which was then packaged into a lipid nanoparticle (LNP) carrier. Preclinical screening in a rat model of hypoxia-induced pulmonary vasoconstriction led to selection of a 16-carbon alkyl ester derivative of TRE. The TPD-LNP demonstrated approximately 10-fold lower TRE plasma C max compared to inhaled TRE solution while maintaining an extended vasodilatory effect. The favorable PK profile is attributed to gradual dissociation of TPD from the LNP and subsequent conversion to TRE. Together, this sustained presentation of TRE to the lungs and plasma is consistent with a once- or twice-daily dosing schedule in the absence of high C max -associated adverse events which could provide patients with an improved treprostinil therapy.
PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
-
Paragraph 00274; 00275; 00276, (2016/11/17)
Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C2-C18 alkyl, branched C3-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described, for example, for administration via subcutaneous or intravenous infusion to a patient in need of pulmonary hypertension treatment. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom.
AMINE SALTS OF A PROSTACYCLIN ANALOG
-
, (2015/06/03)
The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.
